HUTCHMED (China) Limited (AIM:HCM)
191.00
+6.00 (3.24%)
Aug 17, 2026, 10:56 AM GMT
HUTCHMED (China) Employees
HUTCHMED (China) had 1,790 employees as of June 30, 2026.
Employees
1,790
Change
n/a
Growth
n/a
Revenue / Employee
231.21K GBP
Profits / Employee
7.53K GBP
Market Cap
1.61B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 1,790 | - | - |
| Dec 31, 2025 | 1,796 | -15 | -0.83% |
| Dec 31, 2024 | 1,811 | -177 | -8.90% |
| Dec 31, 2023 | 1,988 | -37 | -1.83% |
| Dec 31, 2022 | 2,025 | 265 | 15.06% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Haleon | 24,535 |
| Hikma Pharmaceuticals | 9,400 |
| Allergy Therapeutics | 584 |
| ECO Animal Health Group | 200 |
| Shield Therapeutics | 61 |
| Venture Life Group | 43 |
| Chill Brands Group | 11 |
| Provexis | 2 |
HUTCHMED (China) News
- 9 hours ago - Hutchmed announces results from Saffron Phase III trial of Orpathys, Tagrisso - TheFly
- 10 hours ago - HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO® - GlobeNewsWire
- 17 days ago - HUTCHMED H1 Earnings Call Highlights - MarketBeat
- 17 days ago - HUTCHMED (China) Earnings Call Transcript: H1 2026 - Transcripts
- 17 days ago - HUTCHMED (China) Quarterly report: H1 2026 - Filings
- 17 days ago - HUTCHMED (China) Slides: H1 2026 - Filings
- 24 days ago - Hutchmed price target lowered to $14 from $16 at Goldman Sachs - TheFly
- 27 days ago - A Look at HUTCHMED (China) Ltd (HCM) After 4.4% Gain -- GF Value $13.93 vs Price $11.29 - GuruFocus